Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
 - EconoTimes)
Uppsala, Sweden, December 21, 2016 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today presented positive results from a recently completed dose-finding study of weekly administration of Apealea (Paclical).
The study included 48 patients with metastatic breast cancer that were treated weekly with Apealea (Paclical) starting at 100 mg/m2 and increasing in steps of 10 mg/m2 until 250 mg/m2 was reached. The pre-defined, dose-limiting toxicity as defined in the study protocol was not reached until 250 mg/m2 per week. An overall analysis of all adverse events recorded in the study defined 180 mg/m2 as the level for dose-limiting toxicity. The suggested dose for further development of weekly administration of Apealea is 170 mg/m2.
29 patients continued in a follow-up study for an additional one (1) to 22 weekly cycle(s). Efficacy was assessed through computed tomography in 26 patients: one (1) had complete response, two (2) partial responses, and 23 stable disease. The remaining three (3) patients left the study due to progressive disease. The safety assessments of the follow-up study confirmed the dose of 170 mg/m2 as suitable for further development.
“We are pleased to present results indicating our dosing regime is becoming increasingly accurate and tolerable for patients,” said Margareta Eriksson, Vice President of Clinical Development at Oasmia Pharmaceutical. “This study within the indication of breast cancer, one that affects so many women worldwide, positions Apealea as having significant potential for both patients as well as the physicians who treat them.”
Notes to editors:
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
http://www.globenewswire.com/NewsRoom/AttachmentNg/b1e690fe-c304-440f-a5f7-1e66b78fc20d
Julian Aleksov, Executive Vice Chairman Phone: +46 18 50 54 40 E-mail: [email protected] For Media Inquiries: Eric Fischgrund [email protected]
